For 0 3 0 3 O
Part 4 8 4 8 O
1 9 10 9 10 O
of 11 13 11 13 O
the 14 17 14 17 O
study 18 23 18 23 O
, 23 24 23 24 O
participants 25 37 25 37 O
must 38 42 38 42 O
have 43 47 43 47 O
histopathologically 48 67 48 67 O
confirmed 68 77 68 77 O
diagnosis 78 87 78 87 O
of 88 90 88 90 O
R 91 92 91 92 B-cancer
/ 92 93 92 93 I-cancer
R 93 94 93 94 I-cancer
, 94 95 94 95 O
DLBCL 96 101 96 101 B-cancer
, 101 102 101 102 O
FL 103 105 103 105 B-cancer
, 105 106 105 106 O
MZL 107 110 107 110 B-cancer
/ 110 111 110 111 I-cancer
MALT 111 115 111 115 I-cancer
, 115 116 115 116 O
MCL 117 120 117 120 B-cancer
, 120 121 120 121 O
or 122 124 122 124 O
other 125 130 125 130 O
Sponsor 131 138 131 138 O
approved 139 147 139 147 O
NHL 148 151 148 151 B-cancer
subtypes 152 160 152 160 O
according 161 170 161 170 O
to 171 173 171 173 O
the 174 177 174 177 O
World 178 183 178 183 O
Health 184 190 184 190 O
Organization 191 203 191 203 O
( 204 205 204 205 O
WHO 205 208 205 208 O
) 208 209 208 209 O
classification 210 224 210 224 O
2008 225 229 225 229 O
for 230 233 230 233 O
which 234 239 234 239 O
standard 240 248 240 248 O
measures 249 257 249 257 O
do 258 260 258 260 O
not 261 264 261 264 O
exist 265 270 265 270 O
or 271 273 271 273 O
are 274 277 274 277 O
no 278 280 278 280 O
longer 281 287 281 287 O
effective 288 297 288 297 O

For 0 3 298 301 O
Part 4 8 302 306 O
2 9 10 307 308 O
and 11 14 309 312 O
Part 15 19 313 317 O
3 20 21 318 319 O
of 22 24 320 322 O
the 25 28 323 326 O
study 29 34 327 332 O
, 34 35 332 333 O
participants 36 48 334 346 O
must 49 53 347 351 O
have 54 58 352 356 O
histopathologically 59 78 357 376 O
and 79 82 377 380 O
clinically 83 93 381 391 O
confirmed 94 103 392 401 O
diagnosis 104 113 402 411 O
of 114 116 412 414 O
relapsed 117 125 415 423 O
DLBCL 126 131 424 429 B-cancer

For 0 3 430 433 O
Part 4 8 434 438 O
2 9 10 439 440 O
and 11 14 441 444 O
Part 15 19 445 449 O
3 20 21 450 451 O
of 22 24 452 454 O
the 25 28 455 458 O
study 29 34 459 464 O
, 34 35 464 465 O
participants 36 48 466 478 O
that 49 53 479 483 O
are 54 57 484 487 O
eligible 58 66 488 496 O
to 67 69 497 499 O
undergo 70 77 500 507 O
first 78 83 508 513 B-treatment
time 84 88 514 518 I-treatment
HD 89 91 519 521 I-treatment
- 91 92 521 522 I-treatment
ASCT 92 96 522 526 I-treatment

For 0 3 527 530 O
Part 4 8 531 535 O
2 9 10 536 537 O
and 11 14 538 541 O
Part 15 19 542 546 O
3 20 21 547 548 O
of 22 24 549 551 O
the 25 28 552 555 O
study 29 34 556 561 O
, 34 35 561 562 O
patients 36 44 563 571 O
with 45 49 572 576 O
primary 50 57 577 584 B-chronic_disease
refractory 58 68 585 595 I-chronic_disease
DLBCL 69 74 596 601 I-chronic_disease
( 75 76 602 603 O
defined 76 83 603 610 O
as 84 86 611 613 O
progression 87 98 614 625 O
of 99 101 626 628 O
disease 102 109 629 636 O
within 110 116 637 643 O
24 117 119 644 646 B-upper_bound
weeks 120 125 647 652 I-upper_bound
after 126 131 653 658 O
first 132 137 659 664 O
line 138 142 665 669 O
of 143 145 670 672 O
treatment 146 155 673 682 O
) 155 156 682 683 O

Participants 0 12 684 696 O
must 13 17 697 701 O
have 18 22 702 706 O
Eastern 23 30 707 714 B-clinical_variable
Cooperative 31 42 715 726 I-clinical_variable
Oncology 43 51 727 735 I-clinical_variable
Group 52 57 736 741 I-clinical_variable
( 58 59 742 743 I-clinical_variable
ECOG 59 63 743 747 I-clinical_variable
) 63 64 747 748 I-clinical_variable
Performance 65 76 749 760 I-clinical_variable
Status 77 83 761 767 I-clinical_variable
0 84 85 768 769 B-lower_bound
- 86 87 770 771 O
2 88 89 772 773 B-upper_bound

Participants 0 12 774 786 O
must 13 17 787 791 O
have 18 22 792 796 O
evaluable 23 32 797 806 O
or 33 35 807 809 O
measurable 36 46 810 820 O
disease 47 54 821 828 O
in 55 57 829 831 O
accordance 58 68 832 842 O
with 69 73 843 847 O
the 74 77 848 851 O
International 78 91 852 865 O
Working 92 99 866 873 O
Group 100 105 874 879 O
Guidelines 106 116 880 890 O
for 117 120 891 894 O
Lymphoma 121 129 895 903 B-cancer

Participants 0 12 904 916 O
must 13 17 917 921 O
have 18 22 922 926 O
received 23 31 927 935 O
at 32 34 936 938 O
least 35 40 939 944 O
one 41 44 945 948 B-lower_bound
but 45 48 949 952 O
no 49 51 953 955 O
more 52 56 956 960 O
than 57 61 961 965 O
six 62 65 966 969 B-upper_bound
prior 66 71 970 975 O
treatment 72 81 976 985 O
regimens 82 90 986 994 O

Participants 0 12 995 1007 O
who 13 16 1008 1011 O
are 17 20 1012 1015 O
Hepatitis 21 30 1016 1025 B-chronic_disease
B 31 32 1026 1027 I-chronic_disease
surface 33 40 1028 1035 I-chronic_disease
antigen 41 48 1036 1043 I-chronic_disease
positive 49 57 1044 1052 I-chronic_disease
( 58 59 1053 1054 I-chronic_disease
HBsAg+ 59 65 1054 1060 I-chronic_disease
) 65 66 1060 1061 I-chronic_disease
( 67 68 1062 1063 O
must 68 72 1063 1067 O
be 73 75 1068 1070 O
PCR 76 79 1071 1074 O
negative 80 88 1075 1083 O
) 88 89 1083 1084 O
who 90 93 1085 1088 O
are 94 97 1089 1092 O
taking 98 104 1093 1099 O
antivirals 105 115 1100 1110 O
, 115 116 1110 1111 O
are 117 120 1112 1115 O
allowed 121 128 1116 1123 O
to 129 131 1124 1126 O
enroll 132 138 1127 1133 O

Participants 0 12 1134 1146 O
who 13 16 1147 1150 O
have 17 21 1151 1155 O
known 22 27 1156 1161 O
central 28 35 1162 1169 B-cancer
nervous 36 43 1170 1177 I-cancer
system 44 50 1178 1184 I-cancer
, 50 51 1184 1185 O
meningeal 52 61 1186 1195 B-cancer
, 61 62 1195 1196 O
or 63 65 1197 1199 O
epidural 66 74 1200 1208 B-cancer
disease 75 82 1209 1216 I-cancer
including 83 92 1217 1226 O
brain 93 98 1227 1232 B-cancer
metastases 99 109 1233 1243 I-cancer

Participants 0 12 1244 1256 O
who 13 16 1257 1260 O
have 17 21 1261 1265 O
received 22 30 1266 1274 O
prior 31 36 1275 1280 B-treatment
therapy 37 44 1281 1288 I-treatment
with 45 49 1289 1293 O
other 50 55 1294 1299 B-treatment
anti 56 60 1300 1304 I-treatment
- 60 61 1304 1305 I-treatment
CD37 61 65 1305 1309 I-treatment
- 65 66 1309 1310 I-treatment
targeting 66 75 1310 1319 I-treatment
therapy 76 83 1320 1327 I-treatment

Participants 0 12 1328 1340 O
who 13 16 1341 1344 O
received 17 25 1345 1353 O
at 26 28 1354 1356 O
least 29 34 1357 1362 O
only 35 39 1363 1367 O
one 40 43 1368 1371 B-lower_bound
line 44 48 1372 1376 O
of 49 51 1377 1379 O
previous 52 60 1380 1388 B-treatment
therapy 61 68 1389 1396 I-treatment
and 69 72 1397 1400 O
achieved 73 81 1401 1409 O
either 82 88 1410 1416 O
complete 89 97 1417 1425 B-clinical_variable
response 98 106 1426 1434 I-clinical_variable
( 107 108 1435 1436 I-clinical_variable
CR 108 110 1436 1438 I-clinical_variable
) 110 111 1438 1439 I-clinical_variable
or 112 114 1440 1442 O
partial 115 122 1443 1450 B-treatment
response 123 131 1451 1459 I-treatment
( 132 133 1460 1461 I-treatment
PR 133 135 1461 1463 I-treatment
) 135 136 1463 1464 I-treatment
for 137 140 1465 1468 O
at 141 143 1469 1471 O
least 144 149 1472 1477 O
24 150 152 1478 1480 B-lower_bound
weeks 153 158 1481 1486 I-lower_bound
( 159 160 1487 1488 O
from 160 164 1488 1492 O
the 165 168 1493 1496 O
last 169 173 1497 1501 O
day 174 177 1502 1505 O
of 178 180 1506 1508 O
the 181 184 1509 1512 O
last 185 189 1513 1517 O
cycle 190 195 1518 1523 O
) 195 196 1523 1524 O
after 197 202 1525 1530 O
their 203 208 1531 1536 O
first 209 214 1537 1542 O
line 215 219 1543 1547 O
of 220 222 1548 1550 O
therapy 223 230 1551 1558 O
, 230 231 1558 1559 O
but 232 235 1560 1563 O
are 236 239 1564 1567 O
not 240 243 1568 1571 O
eligible 244 252 1572 1580 O
for 253 256 1581 1584 O
high 257 261 1585 1589 O
dose 262 266 1590 1594 O
chemotherapy 267 279 1595 1607 B-treatment
with 280 284 1608 1612 O
autologous 285 295 1613 1623 B-treatment
stem 296 300 1624 1628 I-treatment
cell 301 305 1629 1633 I-treatment
transplantation 306 321 1634 1649 I-treatment
( 322 323 1650 1651 I-treatment
HD 323 325 1651 1653 I-treatment
- 325 326 1653 1654 I-treatment
ASCT 326 330 1654 1658 I-treatment
) 330 331 1658 1659 I-treatment

Participants 0 12 1660 1672 O
who 13 16 1673 1676 O
received 17 25 1677 1685 O
more 26 30 1686 1690 O
than 31 35 1691 1695 O
one 36 39 1696 1699 O
line 40 44 1700 1704 O
of 45 47 1705 1707 O
previous 48 56 1708 1716 O
therapy 57 64 1717 1724 B-treatment
( 65 66 1725 1726 O
including 66 75 1726 1735 O
HD 76 78 1736 1738 B-treatment
- 78 79 1738 1739 I-treatment
ASCT 79 83 1739 1743 I-treatment
) 83 84 1743 1744 O
, 84 85 1744 1745 O
and 86 89 1746 1749 O
have 90 94 1750 1754 O
achieved 95 103 1755 1763 O
a 104 105 1764 1765 O
duration 106 114 1766 1774 O
of 115 117 1775 1777 O
response 118 126 1778 1786 O
( 127 128 1787 1788 O
CR 128 130 1788 1790 B-treatment
or 131 133 1791 1793 O
PR 134 136 1794 1796 B-treatment
) 136 137 1796 1797 O
of 138 140 1798 1800 O
at 141 143 1801 1803 O
least 144 149 1804 1809 O
8 150 151 1810 1811 B-lower_bound
weeks 152 157 1812 1817 I-lower_bound
( 158 159 1818 1819 O
from 159 163 1819 1823 O
the 164 167 1824 1827 O
last 168 172 1828 1832 O
day 173 176 1833 1836 O
of 177 179 1837 1839 O
the 180 183 1840 1843 O
last 184 188 1844 1848 O
cycle 189 194 1849 1854 O
) 194 195 1854 1855 O
after 196 201 1856 1861 O
their 202 207 1862 1867 O
last 208 212 1868 1872 O
line 213 217 1873 1877 O
of 218 220 1878 1880 O
therapy 221 228 1881 1888 O

Participants 0 12 1889 1901 O
will 13 17 1902 1906 O
be 18 20 1907 1909 O
considered 21 31 1910 1920 O
to 32 34 1921 1923 O
have 35 39 1924 1928 O
a 40 41 1929 1930 O
relapsed 42 50 1931 1939 O
disease 51 58 1940 1947 O
if 59 61 1948 1950 O
they 62 66 1951 1955 O
showed 67 73 1956 1962 O
a 74 75 1963 1964 O
duration 76 84 1965 1973 O
of 85 87 1974 1976 O
response 88 96 1977 1985 O
of 97 99 1986 1988 O
at 100 102 1989 1991 O
least 103 108 1992 1997 O
24 109 111 1998 2000 B-lower_bound
weeks 112 117 2001 2006 I-lower_bound
after 118 123 2007 2012 O
their 124 129 2013 2018 O
first 130 135 2019 2024 B-treatment
line 136 140 2025 2029 I-treatment
of 141 143 2030 2032 I-treatment
therapy 144 151 2033 2040 I-treatment

Participants 0 12 2041 2053 O
with 13 17 2054 2058 O
a 18 19 2059 2060 O
diagnosis 20 29 2061 2070 O
of 30 32 2071 2073 O
chronic 33 40 2074 2081 B-cancer
lymphocytic 41 52 2082 2093 I-cancer
leukemia 53 61 2094 2102 I-cancer
( 62 63 2103 2104 I-cancer
CLL 63 66 2104 2107 I-cancer
) 66 67 2107 2108 I-cancer
or 68 70 2109 2111 O
small 71 76 2112 2117 B-cancer
lymphocytic 77 88 2118 2129 I-cancer
lymphoma 89 97 2130 2138 I-cancer
( 98 99 2139 2140 I-cancer
SLL 99 102 2140 2143 I-cancer
) 102 103 2143 2144 I-cancer

Participants 0 12 2145 2157 O
with 13 17 2158 2162 O
active 18 24 2163 2169 O
hepatitis 25 34 2170 2179 B-chronic_disease
A 35 36 2180 2181 I-chronic_disease
, 36 37 2181 2182 I-chronic_disease
B 38 39 2183 2184 I-chronic_disease
or 40 42 2185 2187 I-chronic_disease
C 43 44 2188 2189 I-chronic_disease
infection 45 54 2190 2199 I-chronic_disease

Participants 0 12 2200 2212 O
with 13 17 2213 2217 O
impaired 18 26 2218 2226 B-chronic_disease
cardiac 27 34 2227 2234 I-chronic_disease
function 35 43 2235 2243 I-chronic_disease
or 44 46 2244 2246 O
clinically 47 57 2247 2257 B-chronic_disease
significant 58 69 2258 2269 I-chronic_disease
cardiac 70 77 2270 2277 I-chronic_disease
disease 78 85 2278 2285 I-chronic_disease

Prior 0 5 2286 2291 O
treatment 6 15 2292 2301 O
with 16 20 2302 2306 O
an 21 23 2307 2309 O
anti 24 28 2310 2314 B-treatment
- 28 29 2314 2315 I-treatment
CD20 29 33 2315 2319 I-treatment
agent 34 39 2320 2325 I-treatment
, 39 40 2325 2326 O
either 41 47 2327 2333 O
alone 48 53 2334 2339 O
or 54 56 2340 2342 O
in 57 59 2343 2345 O
combination 60 71 2346 2357 O
, 71 72 2357 2358 O
is 73 75 2359 2361 O
allowed 76 83 2362 2369 O

The 0 3 2370 2373 O
following 4 13 2374 2383 O
participants 14 26 2384 2396 O
with 27 31 2397 2401 O
relapsed 32 40 2402 2410 O
DLBCL 41 46 2411 2416 B-cancer
will 47 51 2417 2421 O
be 52 54 2422 2424 O
enrolled 55 63 2425 2433 O

Women 0 5 2434 2439 B-gender
who 6 9 2440 2443 O
are 10 13 2444 2447 B-pregnancy
pregnant 14 22 2448 2456 I-pregnancy
or 23 25 2457 2459 O
breast 26 32 2460 2466 O
feeding 33 40 2467 2474 O

